$12.79
51.36% yesterday
Nasdaq, Nov 25, 10:17 pm CET
ISIN
US48669G1058
Symbol
KZIA

Kazia Therapeutics Ltd Sponsored ADR Stock price

$12.79
+5.49 75.21% 1M
+9.21 257.26% 6M
+3.94 44.52% YTD
-14.66 53.41% 1Y
-19.20 60.02% 3Y
-479.71 97.40% 5Y
-505.21 97.53% 10Y
-6,963.09 99.82% 20Y
Nasdaq, Closing price Tue, Nov 25 2025
+4.34 51.36%
ISIN
US48669G1058
Symbol
KZIA
Industry

Key metrics

Basic
Market capitalization
$14.0m
Enterprise Value
$13.4m
Net debt
positive
Cash
$2.8m
Shares outstanding
809.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
199.3 | 423.0
EV/Sales
191.9 | 407.2
EV/FCF
-
P/B
negative
Financial Health
Equity Ratio
-137.0%
Return on Equity
249.4%
ROCE
230.4%
ROIC
432.5%
Debt/Equity
-0.4
Financials (TTM | estimate)
Revenue
$70.0k | $33.0k
EBITDA
- | -
EBIT
$-11.9m | $-21.5m
Net Income
$-13.4m | $-755.4m
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
-95.3% | -52.9%
EBITDA
- | -
EBIT
32.7% | -82.3%
Net Income
22.7% | -5,541.6%
Free Cash Flow
-
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-16,149.1%
Net
-18,159.7% | -2,290,658.6%
Free Cash Flow
-
More
EPS
$0.0
FCF per Share
-
Short interest
1.2%
Employees
13
Rev per Employee
$10.0k
Show more

Is Kazia Therapeutics Ltd Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,053 stocks worldwide.

Kazia Therapeutics Ltd Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Kazia Therapeutics Ltd Sponsored ADR forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Kazia Therapeutics Ltd Sponsored ADR forecast:

Buy
88%
Hold
13%

Financial data from Kazia Therapeutics Ltd Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
0.07 0.07
95% 95%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 5.64 5.64
36% 36%
8,057%
- Research and Development Expense 4.74 4.74
58% 58%
6,771%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -12 -12
33% 33%
-17,017%
Net Profit -13 -13
23% 23%
-19,129%

In millions USD.

Don't miss a Thing! We will send you all news about Kazia Therapeutics Ltd Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kazia Therapeutics Ltd Sponsored ADR Stock News

Neutral
PRNewsWire
7 days ago
SYDNEY , Nov. 18, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (Nasdaq: KZIA), an oncology-focused drug development company, today announced that a patient with stage IV triple-negative breast cancer (TNBC) treated under an FDA-authorized single-patient expanded access protocol combining paxalisib with pembrolizumab (Keytruda®) and standard chemotherapy has achieved an initial immune-complet...
Neutral
PRNewsWire
30 days ago
SYDNEY , Oct. 27, 2025 /PRNewswire/ -- Kazia Therapeutics Limited ("Kazia" or the "Company") today announced its intention to request and hold a follow-up Type C meeting with the U.S. Food & Drug Administration (FDA) to discuss overall survival (OS) findings in newly diagnosed glioblastoma (GBM) patients treated with paxalisib and to seek agency feedback on a potential regulatory pathway aligne...
Neutral
PRNewsWire
about 2 months ago
SYDNEY , Oct. 7, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced an exclusive collaboration and in-licensing agreement (the "Agreement") with QIMR Berghofer for a first-in-class PD-L1 degrader program. The lead optimized compound, NDL2, is an advanced PD-L1 protein degrader currently in development and represents a ne...
More Kazia Therapeutics Ltd Sponsored ADR News

Company Profile

Kazia Therapeutics Ltd. engages in the pharmaceutical drug research and development. Its pipeline includes two clinical-stage drug development candidates such as GDC-0084, and Cantrixil. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.

Head office Australia
CEO John Friend
Employees 13
Founded 1994
Website www.kaziatherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today